Release Therapeutics (previously called MaxiVAX) developed a revolutionary, patented, platform technology for the delivery of highly potent therapeutic proteins to the CNS and beyond. Centered on prioritizing patient needs, this novel platform is a promising therapeutic approach, distinguished by its unique CNS-directed functionality and versatile multi-application capabilities.
View Top Employees from MaxiVAX| Website | http://www.maxivax.ch/home/ |
| Revenue | $5 million |
| Employees | 9 (9 on RocketReach) |
| Founded | 2005 |
| Address | Rue de l'Athénée 24, Genève, Genève 1206, CH |
| Phone | +41 22 552 26 13 |
| Technologies |
JavaScript,
HTML,
PHP
+11 more
(view full list)
|
| Industry | Biotechnology Research, Chemicals, Petrochemicals, Glass & Gases, Biotechnology, Manufacturing, Drug Discovery |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 2834 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular MaxiVAX employee's phone or email?
MaxiVAX Questions
The MaxiVAX annual revenue was $5 million in 2024.
Julien Grogg is the Vice President, Technology of MaxiVAX.
9 people are employed at MaxiVAX.
MaxiVAX is based in Genève, Genève.
The NAICS codes for MaxiVAX are [32, 3254, 32541, 325].
The SIC codes for MaxiVAX are [283, 28, 2834].
Top MaxiVAX Employees
-
2
-
1
-
2
-
1
-
2
